APO Research
Talk to an analyst

APO RESEARCH · REPORT

Diabetic Neuropathic Pain Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Diabetic Neuropathic Pain Drug Industry Growth and Trends Forecast to 2032

26 December 2025116 pages

Choose your research edition.

Industry ResearchDiabetic Neuropathic Pain Drug Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Diabetic Neuropathic Pain Drug Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal Diabetic Neuropathic Pain Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Diabetic Neuropathic Pain Drug Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Diabetic Neuropathic Pain Drug Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Diabetic Neuropathic Pain Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Diabetic Neuropathic Pain Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Diabetic Neuropathic Pain Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Diabetic Neuropathic Pain Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Diabetic Neuropathic Pain Drug include Eli Lilly and Company, Astellas Pharma Inc., AstraZeneca Plc, Theravasc, Inc., Sphaera Pharma Pvt. Ltd., Relmada Therapeutics, Inc., RAPID Pharmaceuticals AG, Pharmaleads and Novaremed, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Diabetic Neuropathic Pain Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Diabetic Neuropathic Pain Drug market size, estimates, and forecasts are presented in terms of sales volume (W Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Diabetic Neuropathic Pain Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Diabetic Neuropathic Pain Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Diabetic Neuropathic Pain Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Diabetic Neuropathic Pain Drug Market by Company

Eli Lilly and Company

Astellas Pharma Inc.

AstraZeneca Plc

Theravasc, Inc.

Sphaera Pharma Pvt. Ltd.

Relmada Therapeutics, Inc.

RAPID Pharmaceuticals AG

Pharmaleads

Novaremed

Mertiva AB

Lohocla Research Corporation

Laboratorios Del Dr. Esteve S.A.

Immune Pharmaceuticals Inc.

Hydra Biosciences, Inc.

Glenmark Pharmaceuticals Ltd.

Dong-A Socio Group

Daiichi Sankyo Company, Limited

Boehringer Ingelheim GmbH

BioDelivery Sciences International, Inc.

Diabetic Neuropathic Pain Drug Segment by Type

AZD-5213

E-52862

GERPOOI

GRC-17536

Filgrastim

Duloxetine Hydrochloride DR

Clonidine Hydrochloride

Others

Diabetic Neuropathic Pain Drug Segment by Application

Clinic

Hospital

Others

Diabetic Neuropathic Pain Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diabetic Neuropathic Pain Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Diabetic Neuropathic Pain Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diabetic Neuropathic Pain Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Diabetic Neuropathic Pain Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Diabetic Neuropathic Pain Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of AZD-5213 Table 2. Major Company of E-52862 Table 3. Major Company of GERPOOI Table 4. Major Company of GRC-17536 Table 5. Major Company of Filgrastim Table 6. Major Company of Duloxetine Hydrochloride DR Table 7. Major Company of Clonidine Hydrochloride Table 8. Major Company of Others Table 9. Global Diabetic Neuropathic Pain Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 10. Global Diabetic Neuropathic Pain Drug Sales by Type (2021-2026) & (W Units) Table 11. Global Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Type (2021-2026) Table 12. Global Diabetic Neuropathic Pain Drug Sales by Type (2021-2026) & (US$ Million) Table 13. Global Diabetic Neuropathic Pain Drug Sales Market Share in Value by Type (2021-2026) Table 14. Global Diabetic Neuropathic Pain Drug Price by Type (2021-2026) & (US$/Unit) Table 15. Global Diabetic Neuropathic Pain Drug Sales by Type (2027-2032) & (W Units) Table 16. Global Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Type (2027-2032) Table 17. Global Diabetic Neuropathic Pain Drug Sales by Type (2027-2032) & (US$ Million) Table 18. Global Diabetic Neuropathic Pain Drug Sales Market Share in Value by Type (2027-2032) Table 19. Global Diabetic Neuropathic Pain Drug Price by Type (2027-2032) & (US$/Unit) Table 20. North America Diabetic Neuropathic Pain Drug Sales by Type (2021-2026) & (W Units) Table 21. North America Diabetic Neuropathic Pain Drug Sales by Type (2021-2026) & (US$ Million) Table 22. Europe Diabetic Neuropathic Pain Drug Sales by Type (2021-2026) & (W Units) Table 23. Europe Diabetic Neuropathic Pain Drug Sales by Type (2021-2026) & (US$ Million) Table 24. Asia-Pacific Diabetic Neuropathic Pain Drug Sales by Type (2021-2026) & (W Units) Table 25. Asia-Pacific Diabetic Neuropathic Pain Drug Sales by Type (2021-2026) & (US$ Million) Table 26. Latin America Diabetic Neuropathic Pain Drug Sales by Type (2021-2026) & (W Units) Table 27. Latin America Diabetic Neuropathic Pain Drug Sales by Type (2021-2026) & (US$ Million) Table 28. Middle East and Africa Diabetic Neuropathic Pain Drug Sales by Type (2021-2026) & (W Units) Table 29. Middle East and Africa Diabetic Neuropathic Pain Drug Sales by Type (2021-2026) & (US$ Million) Table 30. Diabetic Neuropathic Pain Drug Industry Trends Table 31. Diabetic Neuropathic Pain Drug Industry Drivers Table 32. Diabetic Neuropathic Pain Drug Industry Opportunities and Challenges Table 33. Diabetic Neuropathic Pain Drug Industry Restraints Table 34. Global Diabetic Neuropathic Pain Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 35. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Company (2021-2026) Table 36. Global Diabetic Neuropathic Pain Drug Sales by Company (2021-2026) & (W Units) Table 37. Global Diabetic Neuropathic Pain Drug Sales Share by Company (2021-2026) Table 38. Global Diabetic Neuropathic Pain Drug Market Price by Company (2021-2026) & (US$/Unit) Table 39. Global Diabetic Neuropathic Pain Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 40. Global Diabetic Neuropathic Pain Drug Major Company Production Sites and Headquarters Table 41. Global Diabetic Neuropathic Pain Drug Company, Product Type & Application Table 42. Global Diabetic Neuropathic Pain Drug Company Establishment Date Table 43. Global Company Market Concentration Ratio (CR5 and HHI) Table 44. Global Diabetic Neuropathic Pain Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 45. Global Diabetic Neuropathic Pain Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 46. Global Diabetic Neuropathic Pain Drug Sales by Region (2021-2026) & (W Units) Table 47. Global Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Region (2021-2026) Table 48. Global Diabetic Neuropathic Pain Drug Sales by Region (2021-2026) & (US$ Million) Table 49. Global Diabetic Neuropathic Pain Drug Sales Market Share in Value by Region (2021-2026) Table 50. Global Diabetic Neuropathic Pain Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Global Diabetic Neuropathic Pain Drug Sales by Region (2027-2032) & (W Units) Table 52. Global Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Region (2027-2032) Table 53. Global Diabetic Neuropathic Pain Drug Sales by Region (2027-2032) & (US$ Million) Table 54. Global Diabetic Neuropathic Pain Drug Sales Market Share in Value by Region (2027-2032) Table 55. Global Diabetic Neuropathic Pain Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 56. Global Diabetic Neuropathic Pain Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 57. Global Diabetic Neuropathic Pain Drug Sales by Application (2021-2026) & (W Units) Table 58. Global Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Application (2021-2026) Table 59. Global Diabetic Neuropathic Pain Drug Sales by Application (2021-2026) & (US$ Million) Table 60. Global Diabetic Neuropathic Pain Drug Sales Market Share in Value by Application (2021-2026) Table 61. Global Diabetic Neuropathic Pain Drug Price by Application (2021-2026) & (US$/Unit) Table 62. Global Diabetic Neuropathic Pain Drug Sales by Application (2027-2032) & (W Units) Table 63. Global Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Application (2027-2032) Table 64. Global Diabetic Neuropathic Pain Drug Sales by Application (2027-2032) & (US$ Million) Table 65. Global Diabetic Neuropathic Pain Drug Sales Market Share in Value by Application (2027-2032) Table 66. Global Diabetic Neuropathic Pain Drug Price by Application (2027-2032) & (US$/Unit) Table 67. North America Diabetic Neuropathic Pain Drug Sales by Application (2021-2026) & (W Units) Table 68. North America Diabetic Neuropathic Pain Drug Sales by Application (2021-2026) & (US$ Million) Table 69. Europe Diabetic Neuropathic Pain Drug Sales by Application (2021-2026) & (W Units) Table 70. Europe Diabetic Neuropathic Pain Drug Sales by Application (2021-2026) & (US$ Million) Table 71. Asia-Pacific Diabetic Neuropathic Pain Drug Sales by Application (2021-2026) & (W Units) Table 72. Asia-Pacific Diabetic Neuropathic Pain Drug Sales by Application (2021-2026) & (US$ Million) Table 73. Latin America Diabetic Neuropathic Pain Drug Sales by Application (2021-2026) & (W Units) Table 74. Latin America Diabetic Neuropathic Pain Drug Sales by Application (2021-2026) & (US$ Million) Table 75. Middle East and Africa Diabetic Neuropathic Pain Drug Sales by Application (2021-2026) & (W Units) Table 76. Middle East and Africa Diabetic Neuropathic Pain Drug Sales by Application (2021-2026) & (US$ Million) Table 77. Eli Lilly and Company Company Information Table 78. Eli Lilly and Company Business Overview Table 79. Eli Lilly and Company Diabetic Neuropathic Pain Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Eli Lilly and Company Diabetic Neuropathic Pain Drug Product Portfolio Table 81. Eli Lilly and Company Recent Development Table 82. Astellas Pharma Inc. Company Information Table 83. Astellas Pharma Inc. Business Overview Table 84. Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Product Portfolio Table 86. Astellas Pharma Inc. Recent Development Table 87. AstraZeneca Plc Company Information Table 88. AstraZeneca Plc Business Overview Table 89. AstraZeneca Plc Diabetic Neuropathic Pain Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. AstraZeneca Plc Diabetic Neuropathic Pain Drug Product Portfolio Table 91. AstraZeneca Plc Recent Development Table 92. Theravasc, Inc. Company Information Table 93. Theravasc, Inc. Business Overview Table 94. Theravasc, Inc. Diabetic Neuropathic Pain Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Theravasc, Inc. Diabetic Neuropathic Pain Drug Product Portfolio Table 96. Theravasc, Inc. Recent Development Table 97. Sphaera Pharma Pvt. Ltd. Company Information Table 98. Sphaera Pharma Pvt. Ltd. Business Overview Table 99. Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Product Portfolio Table 101. Sphaera Pharma Pvt. Ltd. Recent Development Table 102. Relmada Therapeutics, Inc. Company Information Table 103. Relmada Therapeutics, Inc. Business Overview Table 104. Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Product Portfolio Table 106. Relmada Therapeutics, Inc. Recent Development Table 107. RAPID Pharmaceuticals AG Company Information Table 108. RAPID Pharmaceuticals AG Business Overview Table 109. RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Product Portfolio Table 111. RAPID Pharmaceuticals AG Recent Development Table 112. Pharmaleads Company Information Table 113. Pharmaleads Business Overview Table 114. Pharmaleads Diabetic Neuropathic Pain Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Pharmaleads Diabetic Neuropathic Pain Drug Product Portfolio Table 116. Pharmaleads Recent Development Table 117. Novaremed Company Information Table 118. Novaremed Business Overview Table 119. Novaremed Diabetic Neuropathic Pain Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Novaremed Diabetic Neuropathic Pain Drug Product Portfolio Table 121. Novaremed Recent Development Table 122. Mertiva AB Company Information Table 123. Mertiva AB Business Overview Table 124. Mertiva AB Diabetic Neuropathic Pain Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Mertiva AB Diabetic Neuropathic Pain Drug Product Portfolio Table 126. Mertiva AB Recent Development Table 127. Lohocla Research Corporation Company Information Table 128. Lohocla Research Corporation Business Overview Table 129. Lohocla Research Corporation Diabetic Neuropathic Pain Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Lohocla Research Corporation Diabetic Neuropathic Pain Drug Product Portfolio Table 131. Lohocla Research Corporation Recent Development Table 132. Laboratorios Del Dr. Esteve S.A. Company Information Table 133. Laboratorios Del Dr. Esteve S.A. Business Overview Table 134. Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Product Portfolio Table 136. Laboratorios Del Dr. Esteve S.A. Recent Development Table 137. Immune Pharmaceuticals Inc. Company Information Table 138. Immune Pharmaceuticals Inc. Business Overview Table 139. Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Product Portfolio Table 141. Immune Pharmaceuticals Inc. Recent Development Table 142. Hydra Biosciences, Inc. Company Information Table 143. Hydra Biosciences, Inc. Business Overview Table 144. Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Product Portfolio Table 146. Hydra Biosciences, Inc. Recent Development Table 147. Glenmark Pharmaceuticals Ltd. Company Information Table 148. Glenmark Pharmaceuticals Ltd. Business Overview Table 149. Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 150. Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Product Portfolio Table 151. Glenmark Pharmaceuticals Ltd. Recent Development Table 152. Dong-A Socio Group Company Information Table 153. Dong-A Socio Group Business Overview Table 154. Dong-A Socio Group Diabetic Neuropathic Pain Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 155. Dong-A Socio Group Diabetic Neuropathic Pain Drug Product Portfolio Table 156. Dong-A Socio Group Recent Development Table 157. Daiichi Sankyo Company, Limited Company Information Table 158. Daiichi Sankyo Company, Limited Business Overview Table 159. Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 160. Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Product Portfolio Table 161. Daiichi Sankyo Company, Limited Recent Development Table 162. Boehringer Ingelheim GmbH Company Information Table 163. Boehringer Ingelheim GmbH Business Overview Table 164. Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 165. Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Product Portfolio Table 166. Boehringer Ingelheim GmbH Recent Development Table 167. BioDelivery Sciences International, Inc. Company Information Table 168. BioDelivery Sciences International, Inc. Business Overview Table 169. BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 170. BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Product Portfolio Table 171. BioDelivery Sciences International, Inc. Recent Development Table 172. North America Diabetic Neuropathic Pain Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 173. North America Diabetic Neuropathic Pain Drug Sales by Country (2021-2026) & (W Units) Table 174. North America Diabetic Neuropathic Pain Drug Sales Market Share by Country (2021-2026) Table 175. North America Diabetic Neuropathic Pain Drug Sales Forecast by Country (2027-2032) & (W Units) Table 176. North America Diabetic Neuropathic Pain Drug Sales Market Share Forecast by Country (2027-2032) Table 177. North America Diabetic Neuropathic Pain Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 178. North America Diabetic Neuropathic Pain Drug Market Size by Country (2021-2026) & (US$ Million) Table 179. North America Diabetic Neuropathic Pain Drug Market Share by Country (2021-2026) Table 180. North America Diabetic Neuropathic Pain Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 181. North America Diabetic Neuropathic Pain Drug Market Share Forecast by Country (2027-2032) Table 182. Europe Diabetic Neuropathic Pain Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 183. Europe Diabetic Neuropathic Pain Drug Sales by Country (2021-2026) & (W Units) Table 184. Europe Diabetic Neuropathic Pain Drug Sales Market Share by Country (2021-2026) Table 185. Europe Diabetic Neuropathic Pain Drug Sales Forecast by Country (2027-2032) & (W Units) Table 186. Europe Diabetic Neuropathic Pain Drug Sales Market Share Forecast by Country (2027-2032) Table 187. Europe Diabetic Neuropathic Pain Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 188. Europe Diabetic Neuropathic Pain Drug Market Size by Country (2021-2026) & (US$ Million) Table 189. Europe Diabetic Neuropathic Pain Drug Market Share by Country (2021-2026) Table 190. Europe Diabetic Neuropathic Pain Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 191. Europe Diabetic Neuropathic Pain Drug Market Share Forecast by Country (2027-2032) Table 192. Asia-Pacific Diabetic Neuropathic Pain Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 193. Asia-Pacific Diabetic Neuropathic Pain Drug Sales by Country (2021-2026) & (W Units) Table 194. Asia-Pacific Diabetic Neuropathic Pain Drug Sales Market Share by Country (2021-2026) Table 195. Asia-Pacific Diabetic Neuropathic Pain Drug Sales Forecast by Country (2027-2032) & (W Units) Table 196. Asia-Pacific Diabetic Neuropathic Pain Drug Sales Market Share Forecast by Country (2027-2032) Table 197. Asia-Pacific Diabetic Neuropathic Pain Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 198. Asia-Pacific Diabetic Neuropathic Pain Drug Market Size by Country (2021-2026) & (US$ Million) Table 199. Asia-Pacific Diabetic Neuropathic Pain Drug Market Share by Country (2021-2026) Table 200. Asia-Pacific Diabetic Neuropathic Pain Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 201. Asia-Pacific Diabetic Neuropathic Pain Drug Market Share Forecast by Country (2027-2032) Table 202. Latin America Diabetic Neuropathic Pain Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 203. Latin America Diabetic Neuropathic Pain Drug Sales by Country (2021-2026) & (W Units) Table 204. Latin America Diabetic Neuropathic Pain Drug Sales Market Share by Country (2021-2026) Table 205. Latin America Diabetic Neuropathic Pain Drug Sales Forecast by Country (2027-2032) & (W Units) Table 206. Latin America Diabetic Neuropathic Pain Drug Sales Market Share Forecast by Country (2027-2032) Table 207. Latin America Diabetic Neuropathic Pain Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 208. Latin America Diabetic Neuropathic Pain Drug Market Size by Country (2021-2026) & (US$ Million) Table 209. Latin America Diabetic Neuropathic Pain Drug Market Share by Country (2021-2026) Table 210. Latin America Diabetic Neuropathic Pain Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 211. Latin America Diabetic Neuropathic Pain Drug Market Share Forecast by Country (2027-2032) Table 212. Middle East and Africa Diabetic Neuropathic Pain Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 213. Middle East and Africa Diabetic Neuropathic Pain Drug Sales by Country (2021-2026) & (W Units) Table 214. Middle East and Africa Diabetic Neuropathic Pain Drug Sales Market Share by Country (2021-2026) Table 215. Middle East and Africa Diabetic Neuropathic Pain Drug Sales Forecast by Country (2027-2032) & (W Units) Table 216. Middle East and Africa Diabetic Neuropathic Pain Drug Sales Market Share Forecast by Country (2027-2032) Table 217. Middle East and Africa Diabetic Neuropathic Pain Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 218. Middle East and Africa Diabetic Neuropathic Pain Drug Market Size by Country (2021-2026) & (US$ Million) Table 219. Middle East and Africa Diabetic Neuropathic Pain Drug Market Share by Country (2021-2026) Table 220. Middle East and Africa Diabetic Neuropathic Pain Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 221. Middle East and Africa Diabetic Neuropathic Pain Drug Market Share Forecast by Country (2027-2032) Table 222. Key Raw Materials Table 223. Raw Materials Key Suppliers Table 224. Diabetic Neuropathic Pain Drug Distributors List Table 225. Diabetic Neuropathic Pain Drug Customers List Table 226. Research Programs/Design for This Report Table 227. Authors List of This Report Table 228. Secondary Sources Table 229. Primary Sources List of Figures Figure 1. Diabetic Neuropathic Pain Drug Image Figure 2. Global Diabetic Neuropathic Pain Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Diabetic Neuropathic Pain Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Diabetic Neuropathic Pain Drug Sales (2021-2032) & (W Units) Figure 5. AZD-5213 Image Figure 6. Global AZD-5213 Sales YoY Growth (2021-2032) & (W Units) Figure 7. E-52862 Image Figure 8. Global E-52862 Sales YoY Growth (2021-2032) & (W Units) Figure 9. GERPOOI Image Figure 10. Global GERPOOI Sales YoY Growth (2021-2032) & (W Units) Figure 11. GRC-17536 Image Figure 12. Global GRC-17536 Sales YoY Growth (2021-2032) & (W Units) Figure 13. Filgrastim Image Figure 14. Global Filgrastim Sales YoY Growth (2021-2032) & (W Units) Figure 15. Duloxetine Hydrochloride DR Image Figure 16. Global Duloxetine Hydrochloride DR Sales YoY Growth (2021-2032) & (W Units) Figure 17. Clonidine Hydrochloride Image Figure 18. Global Clonidine Hydrochloride Sales YoY Growth (2021-2032) & (W Units) Figure 19. Others Image Figure 20. Global Others Sales YoY Growth (2021-2032) & (W Units) Figure 21. Global Diabetic Neuropathic Pain Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 22. Global Diabetic Neuropathic Pain Drug Market Share by Type 2025 VS 2032 Figure 23. North America Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Type in 2025 Figure 24. North America Diabetic Neuropathic Pain Drug Sales Market Share in Value by Type in 2025 Figure 25. Europe Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Type in 2025 Figure 26. Europe Diabetic Neuropathic Pain Drug Sales Market Share in Value by Type in 2025 Figure 27. Asia-Pacific Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Type in 2025 Figure 28. Asia-Pacific Diabetic Neuropathic Pain Drug Sales Market Share in Value by Type in 2025 Figure 29. Latin America Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Type in 2025 Figure 30. Latin America Diabetic Neuropathic Pain Drug Sales Market Share in Value by Type in 2025 Figure 31. Middle East and Africa Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Type in 2025 Figure 32. Middle East and Africa Diabetic Neuropathic Pain Drug Sales Market Share in Value by Type in 2025 Figure 33. Global Top 5 and 10 Diabetic Neuropathic Pain Drug Players Market Share by Revenue in 2025 Figure 34. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 35. Clinic Image Figure 36. Global Clinic Sales YoY Growth (2021-2032) & (W Units) Figure 37. Hospital Image Figure 38. Global Hospital Sales YoY Growth (2021-2032) & (W Units) Figure 39. Others Image Figure 40. Global Others Sales YoY Growth (2021-2032) & (W Units) Figure 41. Global Diabetic Neuropathic Pain Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 42. Global Diabetic Neuropathic Pain Drug Market Share by Application 2025 VS 2032 Figure 43. North America Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Application in 2025 Figure 44. North America Diabetic Neuropathic Pain Drug Sales Market Share in Value by Application in 2025 Figure 45. Europe Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Application in 2025 Figure 46. Europe Diabetic Neuropathic Pain Drug Sales Market Share in Value by Application in 2025 Figure 47. Asia-Pacific Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Application in 2025 Figure 48. Asia-Pacific Diabetic Neuropathic Pain Drug Sales Market Share in Value by Application in 2025 Figure 49. Latin America Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Application in 2025 Figure 50. Latin America Diabetic Neuropathic Pain Drug Sales Market Share in Value by Application in 2025 Figure 51. Middle East and Africa Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Application in 2025 Figure 52. Middle East and Africa Diabetic Neuropathic Pain Drug Sales Market Share in Value by Application in 2025 Figure 53. North America Diabetic Neuropathic Pain Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 54. North America Diabetic Neuropathic Pain Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. North America Diabetic Neuropathic Pain Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. North America Diabetic Neuropathic Pain Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Europe Diabetic Neuropathic Pain Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 58. Europe Diabetic Neuropathic Pain Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Diabetic Neuropathic Pain Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Europe Diabetic Neuropathic Pain Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Diabetic Neuropathic Pain Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 62. Asia-Pacific Diabetic Neuropathic Pain Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Diabetic Neuropathic Pain Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Asia-Pacific Diabetic Neuropathic Pain Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Latin America Diabetic Neuropathic Pain Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 66. Latin America Diabetic Neuropathic Pain Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 67. Latin America Diabetic Neuropathic Pain Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 68. Latin America Diabetic Neuropathic Pain Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 69. Middle East and Africa Diabetic Neuropathic Pain Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 70. Middle East and Africa Diabetic Neuropathic Pain Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 71. Middle East and Africa Diabetic Neuropathic Pain Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 72. Middle East and Africa Diabetic Neuropathic Pain Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 73. Diabetic Neuropathic Pain Drug Value Chain Figure 74. Key Raw Materials Price Figure 75. Manufacturing Cost Structure Figure 76. Diabetic Neuropathic Pain Drug Production Mode & Process Figure 77. Direct Comparison with Distribution Share Figure 78. Distributors Profiles Figure 79. Years Considered Figure 80. Research Process Figure 81. Key Executives Interviewed

Scope & coverage.

Types
  • AZD-5213
  • E-52862
  • GERPOOI
  • GRC-17536
  • Filgrastim
  • Duloxetine Hydrochloride DR
  • Clonidine Hydrochloride
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Eli Lilly and Company
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Theravasc, Inc.
  • Sphaera Pharma Pvt. Ltd.
  • Relmada Therapeutics, Inc.
  • RAPID Pharmaceuticals AG
  • Pharmaleads
  • Novaremed
  • Mertiva AB
  • Lohocla Research Corporation
  • Laboratorios Del Dr. Esteve S.A.
  • Immune Pharmaceuticals Inc.
  • Hydra Biosciences, Inc.
  • Glenmark Pharmaceuticals Ltd.
  • Dong-A Socio Group
  • Daiichi Sankyo Company, Limited
  • Boehringer Ingelheim GmbH
  • BioDelivery Sciences International, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Diabetic Neuropathic Pain Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Diabetic Neuropathic Pain Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Diabetic Neuropathic Pain Drug Market by Type
  6. 1.3.1 AZD-5213
  7. 1.3.2 E-52862
  8. 1.3.3 GERPOOI
  9. 1.3.4 GRC-17536
  10. 1.3.5 Filgrastim
  11. 1.3.6 Duloxetine Hydrochloride DR
  12. 1.3.7 Clonidine Hydrochloride
  13. 1.3.8 Others
  14. 1.4 Global Diabetic Neuropathic Pain Drug Market Size by Type
  15. 1.4.1 Global Diabetic Neuropathic Pain Drug Market Size Overview by Type (2021-2032)
  16. 1.4.2 Global Diabetic Neuropathic Pain Drug Historic Market Size Review by Type (2021-2026)
  17. 1.4.3 Global Diabetic Neuropathic Pain Drug Forecasted Market Size by Type (2027-2032)
  18. 1.5 Key Regions Market Size by Type
  19. 1.5.1 North America Diabetic Neuropathic Pain Drug Sales Breakdown by Type (2021-2026)
  20. 1.5.2 Europe Diabetic Neuropathic Pain Drug Sales Breakdown by Type (2021-2026)
  21. 1.5.3 Asia-Pacific Diabetic Neuropathic Pain Drug Sales Breakdown by Type (2021-2026)
  22. 1.5.4 South America Diabetic Neuropathic Pain Drug Sales Breakdown by Type (2021-2026)
  23. 1.5.5 Middle East and Africa Diabetic Neuropathic Pain Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Diabetic Neuropathic Pain Drug Industry Trends
  2. 2.2 Diabetic Neuropathic Pain Drug Industry Drivers
  3. 2.3 Diabetic Neuropathic Pain Drug Industry Opportunities and Challenges
  4. 2.4 Diabetic Neuropathic Pain Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Diabetic Neuropathic Pain Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Diabetic Neuropathic Pain Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Diabetic Neuropathic Pain Drug Price (2021-2026)
  4. 3.4 Global Diabetic Neuropathic Pain Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Diabetic Neuropathic Pain Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Diabetic Neuropathic Pain Drug Company, Product Type & Application
  7. 3.7 Global Diabetic Neuropathic Pain Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Diabetic Neuropathic Pain Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Diabetic Neuropathic Pain Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Diabetic Neuropathic Pain Drug Tier 1, Tier 2, and Tier 3
4 Diabetic Neuropathic Pain Drug Regional Status and Outlook
  1. 4.1 Global Diabetic Neuropathic Pain Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Diabetic Neuropathic Pain Drug Historic Market Size by Region
  3. 4.2.1 Global Diabetic Neuropathic Pain Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Diabetic Neuropathic Pain Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Diabetic Neuropathic Pain Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Diabetic Neuropathic Pain Drug Forecasted Market Size by Region
  7. 4.3.1 Global Diabetic Neuropathic Pain Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Diabetic Neuropathic Pain Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Diabetic Neuropathic Pain Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Diabetic Neuropathic Pain Drug by Application
  1. 5.1 Diabetic Neuropathic Pain Drug Market by Application
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Diabetic Neuropathic Pain Drug Market Size by Application
  6. 5.2.1 Global Diabetic Neuropathic Pain Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Diabetic Neuropathic Pain Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Diabetic Neuropathic Pain Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Diabetic Neuropathic Pain Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Diabetic Neuropathic Pain Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Diabetic Neuropathic Pain Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Diabetic Neuropathic Pain Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Diabetic Neuropathic Pain Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Eli Lilly and Company
  2. 6.1.1 Eli Lilly and Company Company Information
  3. 6.1.2 Eli Lilly and Company Business Overview
  4. 6.1.3 Eli Lilly and Company Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Eli Lilly and Company Diabetic Neuropathic Pain Drug Product Portfolio
  6. 6.1.5 Eli Lilly and Company Recent Developments
  7. 6.2 Astellas Pharma Inc.
  8. 6.2.1 Astellas Pharma Inc. Company Information
  9. 6.2.2 Astellas Pharma Inc. Business Overview
  10. 6.2.3 Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Product Portfolio
  12. 6.2.5 Astellas Pharma Inc. Recent Developments
  13. 6.3 AstraZeneca Plc
  14. 6.3.1 AstraZeneca Plc Company Information
  15. 6.3.2 AstraZeneca Plc Business Overview
  16. 6.3.3 AstraZeneca Plc Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 AstraZeneca Plc Diabetic Neuropathic Pain Drug Product Portfolio
  18. 6.3.5 AstraZeneca Plc Recent Developments
  19. 6.4 Theravasc, Inc.
  20. 6.4.1 Theravasc, Inc. Company Information
  21. 6.4.2 Theravasc, Inc. Business Overview
  22. 6.4.3 Theravasc, Inc. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Theravasc, Inc. Diabetic Neuropathic Pain Drug Product Portfolio
  24. 6.4.5 Theravasc, Inc. Recent Developments
  25. 6.5 Sphaera Pharma Pvt. Ltd.
  26. 6.5.1 Sphaera Pharma Pvt. Ltd. Company Information
  27. 6.5.2 Sphaera Pharma Pvt. Ltd. Business Overview
  28. 6.5.3 Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Product Portfolio
  30. 6.5.5 Sphaera Pharma Pvt. Ltd. Recent Developments
  31. 6.6 Relmada Therapeutics, Inc.
  32. 6.6.1 Relmada Therapeutics, Inc. Company Information
  33. 6.6.2 Relmada Therapeutics, Inc. Business Overview
  34. 6.6.3 Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Product Portfolio
  36. 6.6.5 Relmada Therapeutics, Inc. Recent Developments
  37. 6.7 RAPID Pharmaceuticals AG
  38. 6.7.1 RAPID Pharmaceuticals AG Company Information
  39. 6.7.2 RAPID Pharmaceuticals AG Business Overview
  40. 6.7.3 RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Product Portfolio
  42. 6.7.5 RAPID Pharmaceuticals AG Recent Developments
  43. 6.8 Pharmaleads
  44. 6.8.1 Pharmaleads Company Information
  45. 6.8.2 Pharmaleads Business Overview
  46. 6.8.3 Pharmaleads Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Pharmaleads Diabetic Neuropathic Pain Drug Product Portfolio
  48. 6.8.5 Pharmaleads Recent Developments
  49. 6.9 Novaremed
  50. 6.9.1 Novaremed Company Information
  51. 6.9.2 Novaremed Business Overview
  52. 6.9.3 Novaremed Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Novaremed Diabetic Neuropathic Pain Drug Product Portfolio
  54. 6.9.5 Novaremed Recent Developments
  55. 6.10 Mertiva AB
  56. 6.10.1 Mertiva AB Company Information
  57. 6.10.2 Mertiva AB Business Overview
  58. 6.10.3 Mertiva AB Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Mertiva AB Diabetic Neuropathic Pain Drug Product Portfolio
  60. 6.10.5 Mertiva AB Recent Developments
  61. 6.11 Lohocla Research Corporation
  62. 6.11.1 Lohocla Research Corporation Company Information
  63. 6.11.2 Lohocla Research Corporation Business Overview
  64. 6.11.3 Lohocla Research Corporation Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Lohocla Research Corporation Diabetic Neuropathic Pain Drug Product Portfolio
  66. 6.11.5 Lohocla Research Corporation Recent Developments
  67. 6.12 Laboratorios Del Dr. Esteve S.A.
  68. 6.12.1 Laboratorios Del Dr. Esteve S.A. Company Information
  69. 6.12.2 Laboratorios Del Dr. Esteve S.A. Business Overview
  70. 6.12.3 Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Product Portfolio
  72. 6.12.5 Laboratorios Del Dr. Esteve S.A. Recent Developments
  73. 6.13 Immune Pharmaceuticals Inc.
  74. 6.13.1 Immune Pharmaceuticals Inc. Company Information
  75. 6.13.2 Immune Pharmaceuticals Inc. Business Overview
  76. 6.13.3 Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Product Portfolio
  78. 6.13.5 Immune Pharmaceuticals Inc. Recent Developments
  79. 6.14 Hydra Biosciences, Inc.
  80. 6.14.1 Hydra Biosciences, Inc. Company Information
  81. 6.14.2 Hydra Biosciences, Inc. Business Overview
  82. 6.14.3 Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Product Portfolio
  84. 6.14.5 Hydra Biosciences, Inc. Recent Developments
  85. 6.15 Glenmark Pharmaceuticals Ltd.
  86. 6.15.1 Glenmark Pharmaceuticals Ltd. Company Information
  87. 6.15.2 Glenmark Pharmaceuticals Ltd. Business Overview
  88. 6.15.3 Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Product Portfolio
  90. 6.15.5 Glenmark Pharmaceuticals Ltd. Recent Developments
  91. 6.16 Dong-A Socio Group
  92. 6.16.1 Dong-A Socio Group Company Information
  93. 6.16.2 Dong-A Socio Group Business Overview
  94. 6.16.3 Dong-A Socio Group Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Dong-A Socio Group Diabetic Neuropathic Pain Drug Product Portfolio
  96. 6.16.5 Dong-A Socio Group Recent Developments
  97. 6.17 Daiichi Sankyo Company, Limited
  98. 6.17.1 Daiichi Sankyo Company, Limited Company Information
  99. 6.17.2 Daiichi Sankyo Company, Limited Business Overview
  100. 6.17.3 Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Product Portfolio
  102. 6.17.5 Daiichi Sankyo Company, Limited Recent Developments
  103. 6.18 Boehringer Ingelheim GmbH
  104. 6.18.1 Boehringer Ingelheim GmbH Company Information
  105. 6.18.2 Boehringer Ingelheim GmbH Business Overview
  106. 6.18.3 Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Product Portfolio
  108. 6.18.5 Boehringer Ingelheim GmbH Recent Developments
  109. 6.19 BioDelivery Sciences International, Inc.
  110. 6.19.1 BioDelivery Sciences International, Inc. Company Information
  111. 6.19.2 BioDelivery Sciences International, Inc. Business Overview
  112. 6.19.3 BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Product Portfolio
  114. 6.19.5 BioDelivery Sciences International, Inc. Recent Developments
7 North America by Country
  1. 7.1 North America Diabetic Neuropathic Pain Drug Sales by Country
  2. 7.1.1 North America Diabetic Neuropathic Pain Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Diabetic Neuropathic Pain Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Diabetic Neuropathic Pain Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Diabetic Neuropathic Pain Drug Market Size by Country
  6. 7.2.1 North America Diabetic Neuropathic Pain Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Diabetic Neuropathic Pain Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Diabetic Neuropathic Pain Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Diabetic Neuropathic Pain Drug Sales by Country
  2. 8.1.1 Europe Diabetic Neuropathic Pain Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Diabetic Neuropathic Pain Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Diabetic Neuropathic Pain Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Diabetic Neuropathic Pain Drug Market Size by Country
  6. 8.2.1 Europe Diabetic Neuropathic Pain Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Diabetic Neuropathic Pain Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Diabetic Neuropathic Pain Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Diabetic Neuropathic Pain Drug Sales by Country
  2. 9.1.1 Asia-Pacific Diabetic Neuropathic Pain Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Diabetic Neuropathic Pain Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Diabetic Neuropathic Pain Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Diabetic Neuropathic Pain Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Diabetic Neuropathic Pain Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Diabetic Neuropathic Pain Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Diabetic Neuropathic Pain Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Diabetic Neuropathic Pain Drug Sales by Country
  2. 10.1.1 South America Diabetic Neuropathic Pain Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Diabetic Neuropathic Pain Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Diabetic Neuropathic Pain Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Diabetic Neuropathic Pain Drug Market Size by Country
  6. 10.2.1 South America Diabetic Neuropathic Pain Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Diabetic Neuropathic Pain Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Diabetic Neuropathic Pain Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Diabetic Neuropathic Pain Drug Sales by Country
  2. 11.1.1 Middle East and Africa Diabetic Neuropathic Pain Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Diabetic Neuropathic Pain Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Diabetic Neuropathic Pain Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Diabetic Neuropathic Pain Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Diabetic Neuropathic Pain Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Diabetic Neuropathic Pain Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Diabetic Neuropathic Pain Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Diabetic Neuropathic Pain Drug Value Chain Analysis
  2. 12.1.1 Diabetic Neuropathic Pain Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Diabetic Neuropathic Pain Drug Production Mode & Process
  7. 12.2 Diabetic Neuropathic Pain Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Diabetic Neuropathic Pain Drug Distributors
  10. 12.2.3 Diabetic Neuropathic Pain Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst